Type 1 diabetes (T1D) results from immune-mediated loss of pancreatic beta cells leading to insulin deficiency. It is the most common form of diabetes in children, and its incidence is on the rise. This article reviews the current knowledge on the genetics of T1D. In particular, we discuss the influence of HLA and non-HLA genes on T1D risk and disease progression through the preclinical stages of the disease, and the development of genetic scores that can be applied to disease prediction. Racial/ethnic differences, challenges and future directions in the genetics of T1D are also discussed.
| INTRODUCTION
Type 1 diabetes (T1D) is the most common form of diabetes in children, as it accounts for approximately 80% of pediatric diabetes cases in the United States. 1 The incidence of T1D is on the rise in the United States and worldwide. [2] [3] [4] The SEARCH for Diabetes in Youth study, a population-based study designed to evaluate diabetes in youth in the United States, estimated 21.7 new cases of T1D per year per 100 000 population between 2002 and 2012, 2 and a prevalence of 1.93 cases for every 1000 children. 5 T1D is most common among non-Hispanic whites (NHW), especially among those of Northern European descent, but it is diagnosed in all races and ethnicities. In fact, a recent report indicated that the rise in T1D incidence in the United States is most pronounced among Hispanics. 2 In contrast, T2D is more common among Hispanic, African-American, American Pacific Islander or American Indian populations than in NHW individuals. 1 There is much variation in T1D incidence in different parts of the world; for example, the incidence of T1D (per 10 5 children per year) ranges from 0.1 in China and Venezuela to 36.8 in Sardinia and 36.5 in Finland. 6, 7 T1D is also diagnosed in adult age, with approximately 30% of patients developing symptoms after 18 years of age. Although T1D represents 10% of adult diabetes cases overall, the absolute number of individuals diagnosed with T1D is likely higher among adults than children given the high incidence of diabetes in adults. 8, 9 The hallmark of T1D is beta-cell loss that leads to insulin deficiency. 10 About 90% of patients develop T1D as the result of the autoimmune destruction of beta-cells (type 1A), as marked by the presence of circulating autoantibodies to islet cell autoantigens.
Autoantibody-negative patients are classified as having "idiopathic T1D", or type 1B, which may include patients with autoimmune diabetes lacking measurable autoantibody responses to common autoantigens 11 as well as patients with rare forms of monogenic diabetes, 12, 13 in addition to autoantibody false negatives.
Autoantibody-negative T1D may be more common in some nonWhite racial groups. 
| HLA region
The HLA region on chromosome 6p21 accounts for approximately 50% of the familial aggregation of T1D and its association with T1D has been known for over 40 years. 29 The strongest association is with HLA DR and DQ. HLA DR and DQ are cell surface receptors that present antigens to T-lymphocytes.
Both DR and DQ are alpha-beta heterodimers. The DR alpha chain is encoded by the DRA locus, and the DR beta chain is encoded by DRB loci. Similarly, DQA1 and DQB1 loci encode the alpha and beta chains, respectively, of the DQ molecule. The DR and DQ loci are highly linked to each other and, to a lesser degree, to other HLA loci. of the general population but only in 1% of children with T1D. [41] [42] [43] Besides DRB1 and DQ alleles, additional genetic factors may contribute to T1D risk. For example, DRB3, DRB4, and DRB5 alleles modify the risk conferred by DRB1. 44 Although the strength of the association is lower than with HLA DR and DQ, HLA-DPB1 and DPA1 are also associated to T1D. 45 However, Class II genes do not completely explain the association between HLA and T1D; HLA Class I genes (A, B, and C) also impact T1D risk 31, 46 as well as age of onset, in interaction with Class II genes (DR and DQ). 47 In particular, the alleles with the strongest association with T1D were the protective B*57:01 (OR = 0.19) and B*39:06, which confers risk (OR = 10.31). 48 HLA class I/peptide antigen complexes play a role in the development of the T-cell repertoire in the thymus and in antigen-specific T-cell-mediated cytotoxicity. 48 Overall, HLA-DQB1 position 57, HLA-DRB1 position 13, and HLA-DRB1 position 71 explain over 90% of the phenotypic variance from the HLA DRB1-DQA1-DQB1 locus, HLA DPB1 contributes to about 1.5% of the variance explained, HLA-A to 1.5% and HLA-B to 1%. 37 A reduction in the frequency of high risk HLA types among individuals diagnosed with T1D has been noted over time, 49, 50 in particular among the youngest children. 51 This finding may suggest a shift in the relative contribution of genetics and environmental factors in the etiology of T1D. For example, elevated body mass index (BMI) accelerates progression to T1D 52 and the current elevated prevalence of obesity may be a factor in a growing subset of new cases of T1D.
| Non-HLA genes
After the HLA region, the insulin gene (INS) has the strongest association with T1D. INS, on chromosome 11p15, tagged by -23HphI (rs689) and +1140A/C (rs3842753) SNPs, harbors 3 major insulin variable number tandem repeats (VNTR) according to the number of repeats. The highest risk is conferred by homozygosity for class I (shortest repeats). These insulin polymorphisms regulate the amount of insulin mRNA in the thymus and are likely to influence the development of immune tolerance to insulin. 53, 54 Besides the genes identified using candidate gene approaches, GWAS have provided a wealth of knowledge on the genetic basis of T1D, and over 50 loci have been associated with this disease 55 (reviewed in 56 ), explaining about 80% of its hereditability. 57 National and international research networks and studies have contributed to these investigations, which often require large sample sizes, for example, the Type 1 Diabetes Genetic Consortium (T1DGC), 58 Diabetes and Autoimmunity Study in the Young (DAISY), 59 Diabetes Prevention Trial-1 (DPT-1), 60 TrialNet,, 61,62 BABYDIAB, 63 FinnDiane, 50 Action LADA, 64 Eurodiab, 65 The Environmental Determinants of Diabetes in the Young (TEDDY), 66 Human Biological Data Interchange type 1 diabetes repository, 40 and Danish study group of Diabetes in Childhood, 67 among others.
The protein tyrosine phosphatase, non-receptor type 22 (PTPN22) (rs2476601 SNP), on chromosome 1p13, which encodes lymphoid specific phosphatase (LYP), a suppressor of T cell activation, is also associated with T1D. 68 A gain of function LYP variant is associated with suppression of TCR signaling 69, 70 and reportedly promotes the survival of autoreactive T-lymphocytes in the thymus. The PTPN22 locus has also been associated with effects on the function of effector T-lymphocytes, regulatory T-lymphocytes and B-lymphocytes in the periphery. 71, 72 Other genes that modify T1D risk include the cytotoxic T-lymphocyte associated protein (CTLA-4) (rs3087243), 73 which is a negative regulator of cytotoxic T cells. It has been recently reported that altered post-transcriptional regulation could mediate the association between CTLA-4 polymorphisms and T1D. 74 In fact, Abatacept (CTLA4-Ig), which selectively binds to CD80/86, blocks the interaction with CD28 and modulates co-stimulation, and has been shown to transiently halt beta-cell loss in individuals recently diagnosed with T1D. 75 Other loci associated with T1D are the interleukin-2 receptor subunit alpha (IL2RA, CD25) HLA genes. 59, 93 In this study, the addition of PTPN22 and UBASH3A
SNPs to HLA-DR, DQ genotyping improved T1D risk prediction. In survival analysis, 45% of general population DAISY children with PTPN22 rs2476601 TT or HLA-DR3/4 and UBASH3A rs11203203 AA genotypes developed diabetes by age 15, compared to 3% of children with all other genotypes. 94 The addition of non-HLA markers to HLA-DR3/4, DQ8 did not improve diabetes prediction in DAISY firstdegree relatives.
The BABYDIAB study follows children of parents with T1D from birth. In this study, a genetic score developed with 8 non-HLA SNPs (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL, and ERBB3) was predictive of T1D in children with high-risk HLA genotypes. 95 BABYDIAB investigators developed a second score that used odds ratios to weigh SNPs, and included HLA in addition to 9 SNPs in the PTPN22, INS, IL2RA, ERBB3, ORMDL3, BACH2, IL27, GLIS3, and RNLS genes. 96 This 10-factor score has recently been tested for prediction of T1D in 2 DAISY cohorts, namely, first-degree relatives,
where it was demonstrated superior to combinations with fewer SNPs, and the general population, where it was not superior to the 3-factor model. 97 Most recently, the Exeter group developed a T1D Genetic Score to identify individuals who became insulin dependent among young adults with diabetes 98 and discriminate T1D from monogenic diabetes. 99 This score was developed studying participants in the Wellcome Trust Case Control Consortium (n = 3887), in which it was highly discriminative of T2D (AUC 0.88). This score was validated in the South West England Cohort, where it predicted insulin deficiency in a group of 20 to 40 y/o young adults with diabetes (n = 223, excluded monogenic and secondary diabetes) (AUC 0.87). The score was developed by taking the first 30 T1D-associated SNPs, ranked and weighed by OR. 98 Using just the first 9 SNPs (ie, DR3/DR4-DQ8, DR3/DR3, DR4-DQ8/DR4-DQ8, DR4-DQ8/X, DR3/X, HLA-24,
HLA-B-57:01, HLADRB1-15, PTPN22, INS, IL2RA, ERBB3) returned similar predictive ability. The same T1D genetic risk score, in another study, could discriminate T1D from monogenic diabetes. 98-100 The T1D-GRS was also highly discriminative of monogenic diabetes (MODY or monogenic neonatal diabetes) and T1D.. 99 
| Genetics and the stages of type 1 diabetes
The onset of T1D symptoms is the clinical manifestation of the disease process that results from the interaction of predisposing genetic factors with environmental exposures, which eventually leads to a Tcell mediated, B-cell facilitated, autoimmune attack on betacells. 101, 102 The presence of islet cell autoantibodies is presently the earliest and more robust biomarker of islet autoimmunity. 103 Autoantibody responses to at least 2 islet antigens define the first stage of ). As strategies for T1D diagnosis and prediction rely more heavily on genetics, it will be important to consider racial and ethnic differences in the genetics of T1D.
| CONCLUSIONS AND FUTURE DIRECTIONS
Decades of research show that genetics play a key role in the etiology and pathogenesis of T1D. An extensive body of knowledge has accumulated on the genetic factors that influence the development of the disease. However, the genetics of T1D are complex and polygenic, and modulated by imprinting (eg, INS 121 ), alternative splicing of islet autoantigen mRNAs (eg, IA-2), 122 gene-gene interaction, and gene-environment interaction, for example, through epigenetic modifications, 87, 123 or mediated by retrovirus 124, 125 A critical application of genetics is to improve prediction so that strategies can be designed and implemented to prevent disease in individuals at risk (reviewed in 105, 126 ). Furthermore, genetics could play a unique role as time-independent tools for the diagnosis of diabetes in the large and growing number of cases with unclear diagnosis, 127, 128 and the prognosis of clinical outcomes in individuals with T1D. Converting our advances in T1D genetics into tools that are applicable to clinical needs is one of the great current challenges that should drive the field. 
